Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.35 |
| ▸ | HTR2C | P28335 | 13/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285969 | 0.88 | POLB (0.34) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL17286070 | 0.88 | POLB (0.34) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL8442130 | 0.86 | HTR2A (0.41) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL17888490 | 0.84 | HTR2A (0.40) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL20329799 | 0.81 | — | — | |
| SCHEMBL19013630 | 0.81 | — | — | |
| SCHEMBL13874489 | 0.79 | MEN1 (0.38) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL20682188 | 0.78 | HRH3 (0.33) | — | |
| SCHEMBL17282199 | 0.78 | — | — | |
| SCHEMBL8435327 | 0.77 | NCF1 (0.39) | HTR2AHTR2CL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | HTR2A 3604/4885HTR2C 2450/4885L3MBTL1 4715/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | HTR2A 3604/4885HTR2C 2450/4885L3MBTL1 4715/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | HTR2A 3604/4885HTR2C 2450/4885L3MBTL1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.